CYDY News and Press, CytoDyn Inc From 12/20/22

Nader Pourhassan, the former CEO of embattled biotech CytoDyn ( OTCQB:CYDY ), has been indicted by a federal court grand jury and accused of conspiracy to defraud investors in regards to the company's HIV candidate leronlimab. The stock is down ~12% in Tuesday afternoon ...

VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it will host a virtual R&D...

CytoDyn ( OTCQB:CYDY ) has voluntarily withdrawn a pending Biologics License Application for its HIV biologic leronlimab due to issues related to data collection and trial monitoring by its contract research organization . The company noted that it does not believe it can ...

Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology indications Webcast to be held Monday, October 31, 2022, at 5:30 AM PT / 8:30 AM ET VANCOUVER, Washington, Oct. 28, 2022 (GLOBE NEWS...

Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board VANCOUVER, Wash., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology compan...

Summary Today, I'll discuss why new leadership brings new opportunities. I'll explain the concept of Net Present Value (NPV) and why it's utilized as a 'strategic assessment tool' to identify high value growth opportunities. The timing on the issuance of the 350M shares CytoDy...

Summary TAMS for Non-Alcoholic Steatohepatitis NASH after topline PH2a results and what it could mean to Cytodyn long term investors. Wall Street modeling of non-revenue generating biotechs. Headwinds and risks involved. Overview CytoDyn Inc. (CYDY) is a Vanc...

The market continues to firm up following a powerful rally in July after the worst first half of any year since the 1970’s. The big news driving gains continues to be a sense that inflation could be set to cool, allowing the US Federal Reserve to slow its pace of tightening. At the sam...

CytoDyn Inc (OTCMKTS: CYDY) shares gained more than 8% closing the day at $0.73. CYDY has a market cap of over 524.8M$. CYDY is a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications. The company had announced the appointment o...

VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Cyrus Arman ...